LKB1 Loss Primes the Serrated Pathway in the Intestine- Gastroenterology Feb.26

Introduction

Peutz–Jeghers syndrome (PJS) is a hereditary cancer-predisposition condition caused by germline mutations in LKB1 (STK11). While patients are known to have an increased risk of gastrointestinal cancers, how partial loss of LKB1 reshapes intestinal epithelium to promote cancer has remained unclear. Traditionally, polyp formation in PJS has been attributed to non-epithelial mechanisms.

This study challenges that view by showing that epithelial LKB1 loss alone is sufficient to reprogram intestinal cells into a premalignant state, closely resembling the serrated colorectal cancer pathway.

The key problem

Clinicians recognise serrated colorectal cancer as biologically distinct, often aggressive, and frequently associated with KRAS mutations and growth factor–driven signaling. What has been missing is a clear early molecular event that explains how epithelial tissue becomes “primed” for this pathway—particularly in hereditary cancer syndromes like PJS.

What the authors did:

Used CRISPR/Cas9 to create intestinal and colonic organoids with:

one defective copy of LKB1 (heterozygous loss), and

complete loss (loss of heterozygosity).

Studied these models with:

imaging,

bulk and single-cell RNA sequencing, and

growth factor dependency experiments.

Validated findings in:

human PJS intestinal tissue, and

sporadic colorectal cancer datasets.

Tested the interaction between LKB1 loss and KRAS mutations.

Key findings clinicians should understand:

1) One “hit” is enough

Loss of just one copy of LKB1 pushes intestinal epithelial cells into a premalignant transcriptional program. This program closely mirrors gene expression patterns seen in serrated colorectal cancer.

2) Loss of heterozygosity amplifies the effect

When the remaining LKB1 allele is lost, the premalignant state is further intensified, strengthening the cancer-prone phenotype.

3) Chronic regeneration becomes the new normal

LKB1-deficient cells show persistent features of tissue regeneration, rather than returning to a stable, differentiated state. This creates a biologically unstable environment favourable to neoplastic transformation.

4) EGFR signalling is central

LKB1 loss leads to increased expression of EGFR ligands and receptors, allowing epithelial cells to grow independently of their normal niche signals—a classic hallmark of early cancer biology.

5) Synergy with KRAS explains serrated CRC risk

When KRAS mutations were introduced, LKB1-deficient organoids showed synergistic growth and transcriptional changes, providing a mechanistic explanation for why LKB1 loss strongly aligns with the serrated cancer pathway.

Why this matters clinically

This work reframes PJS-associated cancer risk as an epithelial-intrinsic process, not merely a stromal or hamartomatous phenomenon.

It provides a biological explanation for why LKB1 mutations are linked to serrated colorectal cancer, both hereditary and sporadic.

It supports the concept that serrated carcinogenesis begins long before visible dysplasia, at the level of epithelial identity and growth control.

It raises future possibilities for:

early risk stratification,

targeted surveillance, and

pathway-based prevention strategies (e.g., EGFR-axis modulation).

Bottom-line takeaway for GastroAGI

Heterozygous LKB1 loss is not benign—it actively reprograms intestinal epithelium into a chronic regenerative, serrated cancer–prone state, long before overt malignancy appears.

One-line GastroAGI takeaway

LKB1 loss sets the molecular stage for serrated colorectal cancer.